Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Erabi, Hisayuki; Okada, Go; Shibasaki, Chiyo; Setoyama, Daiki; Kang, Dongchon; Takamura, Masahiro; Yoshino, Atsuo; Fuchikami, Manabu; Kurata, Akiko; Kato, Takahiro A.; Yamawaki, Shigeto; Okamoto, Yasumasa

doi:10.1038/s41598-020-73918-z

Cited by 59 publications

(59 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, plasma levels of kynurenic acid, a tryptophan derivative, differed between B6 and DBA mice. Plasma kynurenic acid levels have been suggested as a potential predictive and treatment response marker for depression [ 31 , 32 ].…”

Section: Discussionmentioning

confidence: 99%

Behavioral and Metabolome Differences between C57BL/6 and DBA/2 Mouse Strains: Implications for Their Use as Models for Depression- and Anxiety-Like Phenotypes

et al. 2021

View full text Add to dashboard Cite

Mouse models are widely used to study behavioral phenotypes related to neuropsychiatric disorders. However, different mouse strains vary in their inherent behavioral and molecular characteristics, which needs to be taken into account depending on the nature of the study. Here, we performed a detailed behavioral and molecular comparison of C57BL/6 (B6) and DBA/2 (DBA) mice, two inbred strains commonly used in neuropsychiatric research. We analyzed anxiety-related and depression-like traits, quantified hippocampal and plasma metabolite profiles, and assessed total antioxidant capacity (ΤΑC). B6 mice exhibit increased depression-like and decreased anxiety-related behavior compared to DBA mice. Metabolite level differences indicate alterations in amino acid, nucleotide and mitochondrial metabolism that are accompanied by a decreased TACin B6 compared to DBA mice. Our data reveal multiple behavioral and molecular differences between B6 and DBA mouse strains, which should be considered in the experimental design for phenotype, pharmacological and mechanistic studies relevant for neuropsychiatric disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Behavioral and Metabolome Differences between C57BL/6 and DBA/2 Mouse Strains: Implications for Their Use as Models for Depression- and Anxiety-Like Phenotypes

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Preliminary data from one small study among patients with stroke also suggest that the kynurenine pathway may be implicated in PSD and disability [ 48 ]. Kynurenic acid seems to be useful not only in process of diagnosis but also in prediction of the treatment response [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

Early Depression Independently of Other Neuropsychiatric Conditions, Influences Disability and Mortality after Stroke (Research Study—Part of PROPOLIS Study)

et al. 2020

View full text Add to dashboard Cite

Post-stroke depression (PSD) is the most frequent neuropsychiatric consequence of stroke. The nature of the relationship between PSD and mortality still remains unknown. One hypothesis is that PSD could be more frequent in those patients who are more vulnerable to physical disability, a mediator variable for higher level of physical damage related to higher risk of mortality. Therefore, the authors’ objective was to explore the assumption that PSD increases disability after stroke, and secondly, that mortality is higher among patients with PSD regardless of stroke severity and other neuropsychiatric conditions. We included 524 consecutive patients with acute stroke or transient ischemic attack, who were screened for depression between 7–10 days after stroke onset. Physical impairment and death were the outcomes measures at evaluation check points three and 12 months post-stroke. PSD independently increased the level of disability three (OR = 1.94, 95% CI 1.31–2.87, p = 0.001), and 12 months post-stroke (OR = 1.61, 95% CI 1.14–2.48, p = 0.009). PSD was also an independent risk factor for death three (OR = 5.68, 95% CI 1.58–20.37, p = 0.008) and 12 months after stroke (OR = 4.53, 95% CI 2.06–9.94, p = 0.001). Our study shows the negative impact of early PSD on the level of disability and survival rates during first year after stroke and supports the assumption that depression may act as an independent mediator for disability leading to death in patients who are more vulnerable for brain injury.

show abstract

“…Moreover, increasing attention has been paid to the KYN pathway since over 95 percent of TRP metabolites through the KYN pathway, leaving about one percent to the synthesis of serotonin that plays an important role in mood disorder. Kynurenic acid (KYNA) is found to be a diagnostic as well as predicative biomarker for depression, while KYN and KYNA are potential predictive biomarkers for escitalopram treatment in depression [118]. KYNs are agonists or antagonist at the N-methyl-D-aspartate receptor of the glutamatergic nervous system.…”

Section: Other Relevant Biomarkers and Therapeutic Targetsmentioning

confidence: 99%

Crosstalk between Existential Phenomenological Psychotherapy and Neurological Science in Mood and Anxiety Disorders

Balogh¹,

Tanaka²,

Török³

et al. 2021

Preprint

View full text Add to dashboard Cite

Psychotherapy is a comprehensive biological treatment modifying complex underlying cognitive, emotional, behavioral, and regulatory responses in the brain, leading patients with mental illness to a new interpretation of the sense of self and others. Psychotherapy is an art of science integrated with psychology and/or philosophy. Neurological science studies the neurological basis of cognition, memory, and behavior as well as the impact of neurological damage and disease on the functions, and their treatment. Both psychotherapy and neurological science deal with the brain; nevertheless, they continue to stay polarized far. Existential phenomenological psychotherapy (EPP) has been in the forefront of meaning-centered counseling for almost a century. The phenomenological approach in psychotherapy originated in the works of Martin Heidegger, Ludwig Binswanger, Medard Boss and Viktor Frankl, and it has been committed to account for the existential possibilities and limitations of one’s life. EPP provides philosophically rich interpretations and empowers counseling techniques to assist mentally suffering individuals by finding meaning and purpose of life. The approach has proven to be effective in treating mood and anxiety disorders. This narrative review article demonstrates the development of EPP, the therapeutic methodology, evidence-based accounts of its curative techniques, current understanding of mood and anxiety disorders in neurological science, and a possible converging path to translate and integrate meaning-centered psychotherapy and neuroscience, concluding that the existential phenomenological psychotherapy potently plays a synergistic role with the currently prevailing medication-based approaches for the treatment of mood and anxiety disorders.

show abstract

Kynurenic acid is a potential overlapped biomarker between diagnosis and treatment response for depression from metabolome analysis

Cited by 59 publications

References 38 publications

Behavioral and Metabolome Differences between C57BL/6 and DBA/2 Mouse Strains: Implications for Their Use as Models for Depression- and Anxiety-Like Phenotypes

Behavioral and Metabolome Differences between C57BL/6 and DBA/2 Mouse Strains: Implications for Their Use as Models for Depression- and Anxiety-Like Phenotypes

Early Depression Independently of Other Neuropsychiatric Conditions, Influences Disability and Mortality after Stroke (Research Study—Part of PROPOLIS Study)

Crosstalk between Existential Phenomenological Psychotherapy and Neurological Science in Mood and Anxiety Disorders

Contact Info

Product

Resources

About